Skip to content Skip to navigation

Alzheimer’s drug trial seeks answers among genetically predisposed population

May 16, 2012
by Charlene Marietti
| Reprints

Although genetics has been linked to only one form of early-onset Alzheimer’s diseaseand accounts for only a small percentage of patients overall, researchers will soon begin a five-year clinical trial among this population, reports the New York Times. Three hundred members of a large family living in and around Medellín, Colombia are known to have a genetic mutation that results in declines in cognitive impairment beginning around age 45.   

Part of the federal government’s national agendato prevent and treat Alzheimer’s disease, the clinical trial will administer a drug to people who do not yet show signs of impairment. The study is planned to last five years at a cost of $100 million, but some researchers are hopeful that sophisticated tests will indicate whether or not the drug has efficacy in as little as two years.

Memory Care Forum - Focus: Resident Care

Get the latest information on Resident Care, and attend other valuable sessions at this two-day event making education on the research, innovations, and program approaches to memory care a priority.

Philadelphia, May 23-24   |   San Diego, September 22-23
Topics